Can a smart drug deliver a toxic payload directly to cancer cells?

NCT ID NCT07730190

Not yet recruiting Disease control Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The study aims to find a safe dose and understand how the drug behaves in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental antibody-drug conjugate called TQB6426 that targets a protein (GPC3) found on some cancer cells
What this could lead to: If safe and effective, TQB6426 could offer a new treatment option for people with advanced cancers that express the GPC3 protein.
What could go wrong: This is an early phase 1 trial, so the drug may not work as hoped or could cause serious side effects. It is too soon to know if it will benefit patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANCIES

Contacts and locations

Locations

Fujian Provincial Hospital

Fuzhou, Fujian, 350001, China
Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, 150081, China
Henan Cancer Hospital

Zhengzhou, Henan, 450003, China
Hunan Cancer Hospital

Changsha, Hunan, 410013, China
Peking University First Hospital

Beijing, Beijing Municipality, 100034, China
Renji Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, 200127, China
The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, 230022, China
ZhuJiang Hospital of Southern Medical University

Guangzhou, Guangdong, 510280, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.